Travere Therapeutics, Inc. TVTX Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperations.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s income (loss) from continuing operations, net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s income (loss) from continuing operations, net of tax, attributable to parent?
- Travere Therapeutics, Inc. (TVTX) reported income (loss) from continuing operations, net of tax, attributable to parent of -$36.6M in Q1 2026.
- How has Travere Therapeutics, Inc.'s income (loss) from continuing operations, net of tax, attributable to parent changed year-over-year?
- Travere Therapeutics, Inc.'s income (loss) from continuing operations, net of tax, attributable to parent increased by 11.2% year-over-year, from -$41.23M to -$36.6M.
- What is the long-term trend for Travere Therapeutics, Inc.'s income (loss) from continuing operations, net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s income (loss) from continuing operations, net of tax, attributable to parent has grown at a -30.6% compound annual growth rate (CAGR), from -$217.29M to -$50.26M.